NCCN Guideline Updates

FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments

FDA Approvals, News & Updates, In the News, National Comprehensive Cancer Network (NCCN), NCCN Guideline Updates

FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines. Read More ›

Updated NCCN Guidelines Expand Targeted Therapy Options for Patients with Metastatic NSCLC

By Wayne Kuznar

NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

July 2018, Vol 8, No 7

NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease

By Wayne Kuznar

NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

July 2018, Vol 8, No 7

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

By Wayne Kuznar

Immunotherapy, NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

May 2018, Vol 8, No 5

Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification

By Wayne Kuznar

NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

May 2018, Vol 8, No 5

Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options

By Wayne Kuznar

NCCN Guideline Updates, Multiple Myeloma, Hematologic Malignancies, National Comprehensive Cancer Network (NCCN)

July 2016, Vol 6, No 7